MSCL.TO
Satellos Bioscience Inc.
1W: -12.9%
1M: -52.9%
3M: +1035.1%
YTD: -44.5%
1Y: +1035.1%
3Y: +1948.8%
5Y: +366.7%
C$8.25 ($5.92)
-0.10 (-1.20%)
Weekly Expected Move ±15.2%
C$6
C$7
C$9
C$10
C$11
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market CapC$127.5M ($91.5M)
52W Range6.24-18.98
Volume5,458
Avg Volume42,359
Beta1.08
Dividend—
Analyst Ratings
Company Info
CEOFrancis Gleeson
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2008-01-07
Websitesatellos.com
Royal Bank Plaza
Toronto, ON M5J 2J1
CA
Toronto, ON M5J 2J1
CA
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Latest News
No recent news
Recent Insider Trades
No insider trades found